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Perspectives
Globalization and human interdepen-
dence have created immeasurable value 
for humanity. These forces, however, 
also provide channels for health risks 
to spread throughout the world. Global 
functions for health, such as interna-
tional partnerships or research and 
development, are a rational response 
to global health risks like pandemics or 
globalized supply chains. Self-interest 
compels governments, or donors, to 
provide global functions even though 
their benefits are widely shared the 
world over.
Policy-makers and donors more 
clearly perceive win-win strategies 
for investment in global functions for 
infectious diseases, than for noncom-
municable diseases. However, non-
communicable diseases account for 
two-thirds of low- and middle-income 
country deaths, but receive only 2% 
of donor assistance, while 36% is allo-
cated to human immunodeficiency virus 
(HIV), tuberculosis and malaria.1,2 One 
explanation for this donor imbalance is 
that security from infectious diseases 
is viewed as a global public good that 
requires global cooperation and for-
eign assistance, whereas security from 
noncommunicable diseases is seen as 
a costly private good, best relegated to 
domestic health response. That is, global 
interdependence is widely accepted for 
infectious diseases, but not for noncom-
municable diseases.
Reframing noncommunicable dis-
eases as shared health threats with global 
interdependence, would justify global 
function provision for such diseases as 
a core donor response.
Global susceptibility and 
risk
Societal structures that exploit human 
vulnerabilities, rather than individual 
choices or chance, limit our ability to 
avoid the major noncommunicable 
disease risks. Among these risks are four 
groups of factors: social determinants; 
behavioural biology; commercial deter-
minants; and the physical environment.
First, noncommunicable disease 
susceptibility does not only arise from 
bad choices and chance. While social 
determinants describe a poverty-health 
nexus, noncommunicable diseases affect 
all socioeconomic groups, albeit in dif-
ferent ways.3 Social contagion and so-
cial disadvantage, rather than individual 
choices, are more to blame for noncom-
municable disease susceptibility. Indeed, 
both risk factors and noncommunicable 
diseases spread through social net-
works.4 Social networks, built through 
person to person interactions or at larger 
scales, through media and digital social 
networks, are the backbone of human 
culture, but the influence they exert can 
also provide channels for health risks to 
exploit our vulnerabilities.
Second, behaviours of stress and 
self-preservation leave us vulnerable to 
social influence and are powerful drivers 
of many modifiable noncommunicable 
disease risks, for example tobacco or 
food consumption patterns. Social and 
neurocognitive susceptibility decrease, 
rather than determine, our ability to 
avoid high-risk exposures, especially in 
the most vulnerable groups, such as the 
young or disadvantaged.5
Third, increasingly global phe-
nomena exploit our vulnerabilities. 
Corporations project global influence 
through marketing, supply chains, 
lobbying and social responsibility cam-
paigns. These actions can be produc-
tive when aligned with public health 
interests, such as optimizing essential 
medicine use, but they can harm those 
susceptible when they are not, for in-
stance tobacco use and excessive alco-
hol and processed food consumption, 
and fossil fuel use.6
Finally, the physical environments in 
which humans live and work, strongly in-
fluence noncommunicable disease preva-
lence.7 Sedentarism and calorie-rich diets 
are signs of a shared, global drift towards 
unhealthier lifestyles across countries.
How an interdependent interna-
tional community shares the conse-
quences of the rising noncommunicable 
disease burden is not completely under-
stood. Noncommunicable diseases exact 
an immense drag on national econo-
mies. Projected cumulative losses are of 
47 trillion United States dollars through 
2030,8 but it is unclear how these costs 
will shape global and regional political, 
social and economic landscapes.
The rationale for global 
functions
The increase of noncommunicable dis-
eases is a consequence of global suscep-
tibility and multiplying risk factor expo-
sure. All countries are at risk, because 
globalization is practically impossible to 
avoid. Relying on national responses and 
appealing to personal responsibility to 
control a global problem is insufficient. 
An effective noncommunicable disease 
response requires a full range of tools 
including global functions, which are 
cooperative strategies that transcend 
national sovereignty to solve global 
problems (Fig. 1).
Global functions can target three as-
pects of noncommunicable disease risks:
First, cross-border externalities 
increase noncommunicable disease risk 
exposure. Examples include influences 
from abroad, such as fast food chains 
or trans-border health impacts from 
air pollution.
Second, globally shared needs, such 
as managing private-sector care deliv-
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ery, providing pro-poor integrated care 
models, or scaling-up access to essential 
medicines, require shared solutions.
Finally, there has been insufficient 
action to protect regulation, trade and 
marketing restrictions, and taxes that 
reduce noncommunicable disease risks 
from opposing powerful actors. Power-
ful advocacy to champion the response, 
a critical factor in other successful 
responses, for instance in the HIV 
epidemic, has so far been inadequate 
against those forces.9
Opportunities for global 
functions
Only a fifth of global health assistance is 
directed to global functions, much less 
than needed and with too little focus on 
the shared benefits of noncommunicable 
disease prevention and management.10 
Global functions for noncommunicable 
diseases must leverage global health law 
and governance, resource shared needs, 
and have strong, inclusive leadership.
Global health law and 
governance
Law and governance mechanisms are 
important, but underutilized global 
functions to address domestic and cross-
border commercial noncommunicable 
disease determinants and externalities. 
The Framework Convention on Tobacco 
Control has been critical for mitigat-
ing the harmful effects of globalized 
tobacco, but unevenly implemented.11 
The World Health Organization (WHO) 
Global strategy to reduce the harmful use 
of alcohol12 and the WHO Action plan 
for the prevention and control of NCDs 
2013–202013 recommendations for 
evidence-based, cost–effective interven-
tions addressing unhealthy consump-
tion of alcohol and calorie-rich foods, 
have also been applied unevenly.
Non-binding, so-called soft law instru-
ments, such as global guidance and stan-
dards, influence societal norms, corporate 
conduct and legislative and policy priori-
ties.14 There is a scope for the provision of 
more guidance on how to regulate damag-
ing industries. Global functions should also 
address common legal barriers to noncom-
municable disease prevention, for example 
reforming discriminatory laws counter-
productive to achieving universal health 
coverage (UHC) or providing funding and 
capacity-building that enables countries to 
respond to trade law challenges.
Global governance and accountabil-
ity mechanisms have been established to 
accelerate progress towards sustainable 
development goal (SDG) target 3.4, “by 
2030, reduce by one third premature 
mortality from non-communicable 
diseases through prevention and treat-
ment and promote mental health and 
well-being.” The SDGs explicitly include 
noncommunicable diseases, but their 
inclusive scope may limit attainment 
without strong leadership and funding. 
While legal and governance mechanisms 
are promising, inadequate funding and 
lack of political will continue to present 
barriers to addressing commercial non-
communicable disease determinants.
Global public goods for shared 
needs
Determining health priorities and al-
locating resources at the national level 
is the work of sovereign states; however, 
the global community could do much 
more to address shared noncommuni-
cable disease needs.
Multiparty agreements and platforms 
have effectively disseminated knowledge, 
lowered prices, increased access and eval-
uated the effectiveness of technologies for 
infectious, child and maternal diseases. 
Examples of such agreements are the 
Clinton Health Access Initiative,15 and the 
Global Health Technologies Coalition.16 
These now familiar global public goods 
can be retooled for noncommunicable 
diseases, for which such initiatives are few, 
recent, under-resourced and still unprov-
en, such as the Coalition to increase access 
to noncommunicable disease medicines 
and products initiative.17
Health promotion is critical in the 
long-term, but greater primary health-
care and UHC investments are needed to 
manage the current noncommunicable 
disease burden. While there are several 
ways to achieve UHC, sharing experi-
ences globally, such as that of the Joint 
learning network, can assist countries in 
improving and scaling up their UHC and 
health system strengthening efforts.18
The global research community 
provides valuable data that enlighten 
our understanding of noncommunicable 
disease prevention and control.19 How-
ever, even though major donors have 
supported global noncommunicable 
disease research, such as the Global Al-
liance for Chronic Diseases,20 research 
and development funding allocated 
to noncommunicable diseases in low- 
and middle-income countries is low 
and mostly focused on questions more 
immediately relevant to rich countries, 
such as cancer treatments with low 
cost–effectiveness.
Championing a global response
The field of noncommunicable disease 
needs stronger, more visible global 
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leadership. Both strong advocacy and 
leadership and increased funding can 
create a virtuous cycle that further leads 
to greater actor power and effectiveness. 
Notable and well-funded cases are The 
Global Fund to Fight AIDS, Tuberculo-
sis and Malaria, and Gavi, the Vaccine 
Alliance.
Public health leaders within the 
noncommunicable disease field, such 
as the United Nations interagency task 
force on the prevention and control 
of noncommunicable diseases, or the 
WHO Global coordination mechanism 
on the prevention and control of non-
communicable diseases, have a narrow 
focus and are inadequately supported. 
As a result of these weaknesses, such 
mechanisms are not well equipped to 
manage the broad scope and partner-
ships needed for a successful global 
noncommunicable disease response. 
This situation has even prompted calls 
for the creation of a new independent 
public–private partnership to take the 
lead in the noncommunicable disease 
response.21
A strong, unified voice for people 
living with noncommunicable diseases 
that could leverage the enhanced gov-
ernance mechanisms discussed above 
would also add pressure on powerful 
vested interests opposing disease control 
measures.
Conclusion
The main response to noncommunicable 
diseases must take place downstream at 
the country level, but the overwhelm-
ing cost of country-specific functions 
has discouraged donor action. Global 
functions may represent comparatively 
smaller, upstream investments that do-
nors can provide to all countries, while 
still allowing them autonomy to set their 
own priorities.
The tasks ahead are to further 
define the global functions required 
for noncommunicable diseases and to 
quantify their costs and impacts. Clean 
air, healthy food and living spaces, 
freedom from coercive messages, access 
to high quality care and protection for 
vulnerable populations, should be the 
focus of global functions. Since these are 
global phenomena, they are everybody’s 
business. ■
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